Carbiotix streamlines organisation in preparation for commercial launch
Carbiotix (publ) ("Carbiotix" or "Company") today announces that the Company will streamline the management team for an increased commercial focus as the Company prepares for the launch of CarbiAXOS in 2022. The current Head of Sales Erik Deaner will become Chief Operations Officer (COO) with immediate effect, and Peter Falck will step down as an operational Chief Scientific Officer (CSO) at the AGM, remaining as a Board member and senior advisor to the Company.
Kristofer Cook, CEO of Carbiotix, comments
"I am pleased to communicate that we are streamlining the management team of Carbiotix for an increased commercial focus in preparation for the launch of CarbiAXOS in 2022. The current Head of Sales Erik Deaner will become Chief Operations Officer (COO) with immediate effect. Erik has done a fantastic job since starting at Carbiotix less than a year ago and will now officially take on the role of overseeing all operational activities at the company. Erik and I complement each other extremely well and I look forward to working alongside him as we ramp up commercial activities across all Carbiotix related products and services.
We have also mutually decided that Peter Falck will step away from operational activities as Chief Scientific Officer (CSO) at the AGM in April. Peter will remain as a Board member and senior advisor to the Company. I would personally like to thank Peter for his efforts over the past eight years as an operational CSO. After the AGM, Peter will focus his time on early start-up projects from Lund University and will play a key role in creating a bridge to the university and thus a pipeline of potential new innovations. As a close colleague, I look forward to receiving continued support from Peter as a Board member and senior advisor in the development of Carbiotix going forward. I see this decision for Peter to step down as completely natural, especially as the Company matures and takes on a greater commercial focus. Peter’s operational responsibilities will be taken over by our current Chief Technical Officer (CTO) Stephen Bromley who was hired by Peter and who I have the utmost confidence will perform extremely well in the combined role of CSO and CTO.
We have been working a long time to get to this point in the Company’s development and I look forward to an acceleration of commercial activities in our core business area of selling prebiotic modulators, starting with a nutraceutical ingredient targeting the US market in 2022. This streamlining of the management team will play a key role in this acceleration process."
This is information that Carbiotix AB is obliged to make public according to the EU Market Abuse Regulation (MAR). The information was made publicly available by the Company’s contact person set out below on 16 February 2022.
Forward-looking statements
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
For further information:
Carbiotix AB
Kristofer Cook, CEO
Tel: +46 (0)708-796580
E-mail: kristofer.cook@carbiotix.com
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.